NASDAQ NMS - GLOBAL MARKET · FHTX
+5.58% · +$0.1100 · Vol 917.1K
Market closed · last close 4:00 PM ET · price as of 19:34:31 ET
Foghorn Therapeutics Inc

Foghorn Therapeutics Inc

Biotechnology
$2.08
Card
Relationship Map

Follow $FHTX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $FHTX by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
FHTX
Foghorn Therapeutics Inc
Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

47/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is FHTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading FHTX catalysts
About Foghorn Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
106
Country
US

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.92
Day high
$2.15
Day low
$1.91
Previous close
$1.97
52W high
$7.07
-70.58% from high
52W low
$1.91
3% of range
Market cap
$117M
EPS
$-0.9826
Beta
0.22
Shares out
59.4M
Volume
917.1K
0.93× rel vol
Avg volume
989.8K
VWAP
$2.08
Price history computed in-house
1W
-28.77%
1M
-56.94%
3M
-65.04%
1Y
-53.78%
YTD
-61.48%
SMA 50 $4.92 · below
SMA 200 $5.01 · below
52W position 3%

FHTX overview

Veridion Score
47
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around FHTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading FHTX Form 4 filings
Public disclosures

Congress activity in FHTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

FHTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for FHTX in this window.
Lobbying spend

FHTX lobbying filings, year to date.

Registered lobbying filings matched to Foghorn Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for FHTX in this window.
Loading news for FHTX
Analyst ratings
Sovereign unlock shows live analyst consensus for FHTX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.